Privia Health Group, Inc. — Form 8-K Summary
Reporting period and context: Current report covering executive leadership changes announced in April 2023. Shawn Morris notified the Board on April 7, 2023 that he would retire as Chief Executive Officer effective July 1, 2023, while continuing as a non-employee director. The filing was signed April 12, 2023 and references an April 11 appointment of his successor.
Executive Transition
- Parth Mehrotra, currently President and Chief Operating Officer and in that role since 2018, was appointed CEO effective July 1, 2023.
- Mr. Mehrotra will cease serving as President and COO on the transition date. The Board expects to appoint him as a director upon assuming the CEO role.
- Mr. Morris is expected to remain on the Board following his retirement as CEO.
Financial Terms and Other Key Metrics
- Mr. Mehrotra’s annual base salary as CEO will be $600,000, with a target annual bonus equal to 100% of base salary.
- Subject to Board approval, Mr. Mehrotra will receive an incremental 2023 long-term incentive award valued at $1 million at grant, consisting of 60% performance stock units and 40% time-based restricted stock units.
- Subject to Board approval, he will also receive a one-time $6 million award of performance stock units tied to relative total shareholder return over July 1, 2023 through June 30, 2027. Payout may range from 50% to 200% of the granted units after a threshold performance level is met.
- Mr. Morris will be eligible for a prorated 2023 performance bonus for January 1 through June 30, payable in 2024 subject to corporate performance and bonus-pool funding.
- Mr. Morris’s pre-transition equity awards will remain outstanding and continue vesting under their existing terms until he resigns or is removed from the Board.
- Mr. Morris will receive monthly cash payments equal to COBRA premiums for 12 months after the transition date.
- The filing provides no revenue, profit, cash-flow, margin, debt, liquidity, or other operating-performance metrics for the period.
Material Changes, Outlook, and Risks
The principal material change is the planned CEO succession from Mr. Morris to Mr. Mehrotra. The term sheets are expected to be replaced by formal employment, transition, and separation agreements. Mr. Morris will assist with the transition and remain subject to specified restrictive covenants during his Board tenure and for 18 months thereafter.
The filing does not provide financial guidance or an updated business outlook. Forward-looking statements concerning the transition are subject to execution and other business risks, including the risk that cash from operating activities may not be received in expected amounts or time frames. The company refers investors to the risk factors in its Form 10-K for the year ended December 31, 2022.
Important Facts for Investors to Verify
- Completion of the July 1, 2023 CEO transition and Mr. Mehrotra’s expected appointment to the Board.
- Finalization of Mr. Mehrotra’s amended employment agreement and approval and grant of the $1 million and $6 million equity awards.
- Finalization of Mr. Morris’s transition and separation agreement, including bonus, equity vesting, option-exercise, COBRA, release, and restrictive-covenant provisions.
- Any subsequent disclosures regarding changes in strategy, operating performance, cash flow, or financial guidance following the leadership transition.